Search

Your search keyword '"Turesson, Ingemar"' showing total 710 results

Search Constraints

Start Over You searched for: Author "Turesson, Ingemar" Remove constraint Author: "Turesson, Ingemar"
710 results on '"Turesson, Ingemar"'

Search Results

151. Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation

152. Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase

153. Intensive treatment and stem cell transplantation in chronic myelogenous leukemia : long-term follow-up.

157. MyelomA Genetics International Consortium

158. Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia : BMT prolongs survival.

159. Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia:BMT prolongs survival

160. A low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma

161. The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study

162. Direct evidence for a polygenic etiology in familial multiple myeloma

169. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial

171. Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma

175. Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients.

176. Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial.

178. Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden

188. Germline Genes Specific to Chronic Lymphocytic Leukemia (CLL) and Genes Common to CLL, Lymphoplasmacytic Lymphoma/Waldenström’s Macroglobulinemia, and Other Non-Hodgkin Lymphomas Are Important in Susceptibility

193. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group

194. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma : a population-based study.

197. Increased Risk of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Lymphoproliferative Tumors among 14689 First-Degree Relatives of 4488 MGUS Patients in Sweden.

199. Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma.

Catalog

Books, media, physical & digital resources